{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}],"title":"Stringent Complete Response (sCR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}]}],"title":"Very Good Partial response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"title":"Other Response (progression, stable disease, etc)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Myeloma response criteria developed by Bladé et al. was used to categorize response.","groups":[{"description":"This is the response rate assessed for patients after their bortezomib-based mobilization.","id":"OG000","title":"Treatment Arm - Post Mobilization"},{"description":"This is the overall best response rate (ORR, ≥PR, as measured by ≥50% reduction in M-protein) to DoVeD therapy from post-primary induction (pre-DoVeD).","id":"OG001","title":"Treatment Arm - Responses Prior to Mobilization"}],"paramType":"NUMBER","populationDescription":"All 38 patients were treated with DoVeD consolidation therapy (Vel + DEX with or without DOXIL). Of the 38 patients enrolled, 27 proceeded to mobilization (11 did not undergo mobilization). Responses were assessed prior to mobilization (post DoVED), and again after mobilization, to see if mobilization improved patient response.","reportingStatus":"POSTED","timeFrame":"Best response at any point during each respective study phase was collected - once after consolidation/prior to mobilization (approximately 6 cycles after start of treatment), and once after mobilization","title":"Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate)","type":"PRIMARY","unitOfMeasure":"participants"}